| Interest in New Therapies in Development for Hyperkalemia is High, According ... - Business Wire (press release) |
|
|
Business Wire (press release) (BUSINESS WIRE)--While the perceived need for new therapies for hyperkalemia is relatively low compared to a number of other conditions in nephrology, interest is high in Relypsa's RLY5016, in development for the treatment of hyperkalemia. |